tebu-bio is a European company specialised in providing innovative reagents and laboratory services in Life Sciences

Need an answer now?

Give us a call

Leave a message, we'll get back to you

New SARS-CoV-2 cell based assay

Identified as the entry point of the SARS-CoV-2 virus into cells, the Human Angiotensin converting enzyme 2 (ACE2) represents a very promising target for the development of new Covid-19 treatments.

In addition to a full range of biochemical assays to study Spike:ACE2 interaction we're pleased to offer a combination of tools to study this interaction in a cell based assay format (BPS Biosciences).

  • ACE2 Recombinant cell line

    This recombinant clonal stable cell line constitutively express the full length human ACE2 on their outer membrane. They are mimicking the respiratory tract cells expressing ACE2 and represent a perfect alternative to study the SARS-CoV-2 binding.
  • Spike (SARS-CoV-2) Pseudotyped Lentivirus

    The commonly used VSV-G viral fusion protein, which mediates the fusion between the virus envelope and host cellular membrane, has been here replaced by the by the SARS-CoV-2 Spike protein mimicking Covid-19 virus. In addition a luciferase reporter has been added to easily visualize and measure the pseudotyped lentivirus entry into the cell. 

These two products are a perfect combination to develop your cell based assay and study the SARS-CoV-2 binding and entry into human cells. .

Get your projects fast-tracked!

Our laboratory based near Paris (France) has developed and performs many services to help you in evaluating your current drug portfolio or lead NMEs for anti-COVID-19 therapeutic purposes, but also numerous other research fields.

Interested in testing your portfolio with our SARS-CoV-2/ACE2 in vitro screening assays?
Or testing directly in a physiologically relevant context thanks to these new pseudovirus tools?

Interested in learning more?


Find more in-depth information about these new screening assays in this post on our blog.